Rumænien - rumænsk - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

fhc, inc. -

Rumænien - rumænsk - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

fhc, inc. -

Rumænien - rumænsk - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

fhc, inc. -

Rumænien - rumænsk - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sc medicamed market srl -

Rumænien - rumænsk - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sc medicamed market srl -

Rumænien - rumænsk - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

mundipharma dc b.v. - olanda - metoxifluranum - vapori de inhalat lichid - 99,9% - alte analgezice si antipiretice alte analgezice si antipiretice

Rumænien - rumænsk - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sanofi pasteur - franta - ser antiviperinic - conc. pt. sol. perf. - imunoglobuline imunoglobuline specifice

Den Europæiske Union - rumænsk - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - limfom, mantle-cell - agenți antineoplazici - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Den Europæiske Union - rumænsk - EMA (European Medicines Agency)

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - agenți antineoplazici - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.

Den Europæiske Union - rumænsk - EMA (European Medicines Agency)

astrazeneca ab - ticagrelor - peripheral vascular diseases; acute coronary syndrome - agenți antitrombotici - brilique, co administrat concomitent cu acidul acetilsalicilic (aas), este indicat pentru prevenirea evenimentelor aterotrombotice la pacienții adulți withacute sindroame coronariene (acs) ora antecedente de infarct miocardic acut (ima) și un risc ridicat de a dezvolta o aterotrombotice eventbrilique, administrat concomitent cu acidul acetilsalicilic (aas), este indicat pentru prevenirea evenimentelor aterotrombotice la pacienții adulți cu antecedente de infarct miocardic acut (ima a avut loc cel puțin un an în urmă) și un risc ridicat de a dezvolta o aterotrombotice eveniment.